View in EDS

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

Saved in:
Bibliographic Details
Title: [18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.
Authors: Breukers SE; Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.breukers@nki.nl.; Antoni Van Leeuwenhoek (NKI-AVL), The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.breukers@nki.nl., Crommelin RD; Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Smit LA; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer JP; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Navran A; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Houdt WJ; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Bree R; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Haanen JBAG; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Wondergem M; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zuur CL; Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands., Vogel WV; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. w.vogel@nki.nl.; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands. w.vogel@nki.nl.; Antoni Van Leeuwenhoek (NKI-AVL), The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. w.vogel@nki.nl.
Source: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2026 Mar; Vol. 53 (4), pp. 2217-2233. Date of Electronic Publication: 2025 Oct 28.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1619-7089
DOI:10.1007/s00259-025-07518-2